Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:32 PM
Ignite Modification Date:
2025-12-24 @ 1:32 PM
NCT ID:
NCT03287895
Eligibility Criteria:
Inclusion Criteria:
1. Eligible to receive CPR
2. Satisfying at least one of the following criteria groups
1. 55 years of age or older with one or more of the following diagnoses:
* Chronic obstructive lung disease (2 of the 3 of: baseline PaCO2 of \> 45 torr, cor pulmonale; respiratory failure episode within the preceding year; forced expiratory volume in 1 sec \<0.5 L)
* Congestive heart failure (New York Heart Association class IV symptoms and left ventricular ejection fraction \< 25%)
* Cirrhosis (confirmed by imaging studies or documentation of esophageal varices and one of three conditions; hepatic coma, child's class C liver disease, or child's class B liver disease with gastrointestinal bleeding)
* Cancer (metastatic cancer or stage IV lymphoma)
* End-stage dementia (inability to perform all ADLs, mutism or minimal verbal output secondary to dementia, bed-bound state prior to acute illness).
2. 80 years of age or older and admitted to hospital from the community for an acute medical or surgical condition.
3. If none of the above criteria are met, any patient whose death within the next 6 months would not surprise any member of their care team.
4. At least 55 years old and predicted risk of death in the next 12 months of \>=10% as calculated with the HOMR Now! Score
Exclusion Criteria:
* Patients or SDMs who do not speak English.
* Patients or SDMs who do not provide informed consent.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
55 Years
Study:
NCT03287895
Study Brief:
Protocol Section:
NCT03287895